Development and Validation of a Robust and Modular Host: Guest-based Pretargeting Platform

强大的模块化主机的开发和验证:基于访客的预定位平台

基本信息

  • 批准号:
    9896402
  • 负责人:
  • 金额:
    $ 23.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-17 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Project Summary Molecular imaging approaches that utilize monoclonal antibodies (mAbs) have shown great promise, but their extension into clinical practice is often difficult due to high radiation doses and inconvenient image acquisition intervals. These problems stem from the long-lived radioisotopes that are necessary to match the physiological properties of the mAbs themselves, namely a long in vivo half-life. Several pretargeting platforms, which aim to eliminate the dosimetry concerns by decoupling the radioisotope from the mAb, have been utilized successfully in preclinical models and with limited success in a clinical setting. However, to be widely applicable and translatable, pretargeting systems need to be robust, modular, and compatible for human use, and all of the platforms reported to date have not met those requirements. Broadly, the limitations of the predominant pretargeting platforms reported to date are non-modularity of the pretargeting components, intrinsic instability of the reactive ligands, or immunogenicity. Thus, we believe that taking advantage of the immense potential of pretargeting necessitates the development of a platform that is based on robust ligands that are amenable to a modular approach and are compatible with human use. We propose to develop a platform that meets these rigorous demands by utilizing the “host:guest” pair curcubit[7]uril (CB7) and adamantane (Adma). CB7 is known to rapidly form a strong, noncovalent interaction with Adma ligands, exhibiting similar kinetic and stability properties as biotin and streptavidin. We believe that this host:guest pair is ideal for development of a pretargeting platform for several reasons. First, CB7 may be easily functionalized for attachment to mAbs while Adma can be easily functionalized for radiolabeling with essentially any PET radioisotope, providing the requisite modularity. Additionally, neither functionality susceptible to racemization or prone to degradation, suggesting they are suitably robust. Finally, both CB7- and Adma-containing molecules have been reported as suitable for human use in various forms. Given the exceptional host:guest chemistry between CB7 and Adma-based compounds as well as their satisfaction of the above criteria for successful pretargeting platforms, we propose to develop and evaluate a pretargeted PET platform based on these compounds. The goal of the proposed project is to develop CB7-conjugated mAbs as well as Adma-containing ligands labeled with PET emitting radioisotopes. We will carry out a rigorous optimization of the pretargeting components and test our lead candidates using in vivo murine models of cancer. If successful, our pretargeting system could be the first to fully seize upon this concept of pretargeted PET imaging in a way that is widely applicable for human use. In doing so, we could alter the course of antibody-based PET imaging for precision medicine.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jacob Houghton其他文献

Jacob Houghton的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jacob Houghton', 18)}}的其他基金

Development and Validation of a Robust and Modular Host: Guest-based Pretargeting Platform
强大的模块化主机的开发和验证:基于访客的预定位平台
  • 批准号:
    10265375
  • 财政年份:
    2020
  • 资助金额:
    $ 23.93万
  • 项目类别:
Development and Validation of a Robust and Modular Host: Guest-based Pretargeting Platform
强大的模块化主机的开发和验证:基于访客的预定位平台
  • 批准号:
    10456858
  • 财政年份:
    2020
  • 资助金额:
    $ 23.93万
  • 项目类别:
Developing an Anti-sialyl-Lewisa Diabody for ImmunoPET Imaging of Pancreas Cancer
开发用于胰腺癌免疫 PET 成像的抗唾液酸化 Lewisa 双抗体
  • 批准号:
    8893777
  • 财政年份:
    2014
  • 资助金额:
    $ 23.93万
  • 项目类别:
Developing an Anti-sialyl-Lewisa Diabody for ImmunoPET Imaging of Pancreas Cancer
开发用于胰腺癌免疫 PET 成像的抗唾液酸化 Lewisa 双抗体
  • 批准号:
    8649866
  • 财政年份:
    2014
  • 资助金额:
    $ 23.93万
  • 项目类别:
Developing an Anti-sialyl-Lewisa Diabody for ImmunoPET Imaging of Pancreas Cancer
开发用于胰腺癌免疫 PET 成像的抗唾液酸化 Lewisa 双抗体
  • 批准号:
    9098651
  • 财政年份:
    2014
  • 资助金额:
    $ 23.93万
  • 项目类别:

相似海外基金

New Materials based on Adamantane
基于金刚烷的新材料
  • 批准号:
    550629-2020
  • 财政年份:
    2020
  • 资助金额:
    $ 23.93万
  • 项目类别:
    University Undergraduate Student Research Awards
Modular approach to 1,2-disubstituted adamantane derivatives by directed C-H functionalization reactions
通过定向 C-H 官能化反应制备 1,2-二取代金刚烷衍生物的模块化方法
  • 批准号:
    315058126
  • 财政年份:
    2016
  • 资助金额:
    $ 23.93万
  • 项目类别:
    Research Grants
Development of functional monolayers by successive coupling reaction originating from adamantane tripod on the metal surface
通过金属表面金刚烷三脚连续偶联反应开发功能单层
  • 批准号:
    24550155
  • 财政年份:
    2012
  • 资助金额:
    $ 23.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Adamantane Drug Binding to Membrane-Bound Influenza A M2 Protein
金刚烷药物与膜结合甲型流感 M2 蛋白的结合
  • 批准号:
    8097038
  • 财政年份:
    2011
  • 资助金额:
    $ 23.93万
  • 项目类别:
On-chip supercontinuum generation and advanced spectroscopy on adamantane-type cluster molecules
金刚烷型簇分子的片上超连续谱生成和先进光谱
  • 批准号:
    511825862
  • 财政年份:
  • 资助金额:
    $ 23.93万
  • 项目类别:
    Research Units
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了